Posted on March 9th, 2007 by Brian
Basic Info
Website: http://www.syntapharma.com/
Stock symbol: SNTA
IPO date:2/6/07
Total shares outstanding:33.82M (5M offered at IPO)
Other reviews: Seeking Alpha
Drugs/Platforms
Drugs in trials:
STA-4783 starting Phase 3 trials for treatment of melastatic melanoma
STA-5326 in Phase 2 trials for the treatment of Rheumatoid Arthritus and CVID
Drugs in development:
STA-9090 a heat shock protein inhibitor for the treatment of cancer
STA-9584 a vascular disrupting agent for […]
Filed under: Synta Pharmaceuticals (SNTA) | Comment on this post »
Posted on March 12th, 2007 by Brian
This is part two of the Investment report for Synta Pharmaceuticals.
Melanomas
Synta’s main drug is called STA-4783 which treats melanomas. Melanomas (skin cancer) affect 1 in almost 60 adults in the US in their lifetime. It affects over 60,000 people in the US every year and causes approximately 8,000 deaths. Since melanomas are on […]
Filed under: Synta Pharmaceuticals (SNTA) | 6 Comments »
Posted on March 16th, 2007 by Brian
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 2 posts in the Synta Pharmaceuticals stock evaluation category.
Chronic Inflammatory Diseases
IL-12 and a related protein, IL-23, are cytokines (signaling protein that gets transfered from one cell to another) which stimulates T-cells in the the immune system. T-cells […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
Posted on March 19th, 2007 by Brian
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 3 posts in the Synta Pharmaceuticals stock evaluation category.
I won’t cover the rest of Synta’s drugs in too much detail since they are all relatively early in the pipeline, but here’s a synopsis on each:
STA-9090
STA-9090 is an inhibitor of […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
Posted on March 21st, 2007 by Brian
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 4 posts in the Synta Pharmaceuticals stock evaluation category.
Synta is a fairly small biotech company. As of the middle of January, they had 141 full time employees, 108 of which were engaged in research and development. Over half […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
Posted on March 23rd, 2007 by Brian
This is a continuation of my evaluation of Synta Pharmaceuticals. You can find the first 5 posts in the Synta Pharmaceuticals stock evaluation category.
As I’ve said before, I’m a scientist, not a business major, so feel free to point out in the comments any errors in thinking you find. I guess that goes […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »
Posted on March 28th, 2007 by Brian
The only way to figure out the future value of a biotech company is to figure out how much they might make off of their drugs in clinical trials if they get approved by the FDA. Today, I’ll take a look at the markets for two of Synta’s potential drugs: STA-4784 and Apilimod. […]
Filed under: Synta Pharmaceuticals (SNTA) | Comment on this post »
Posted on March 30th, 2007 by Brian
After the exhaustive analysis of Synta Pharmaceuticals, it’s time to make the call to buy the stock or put it on the watch list (I haven’t seen any real red flags that would lead me to throw it out completely).
My biggest concern is with their cash flow. Even with the cash from […]
Filed under: Synta Pharmaceuticals (SNTA) | 6 Comments »
Posted on April 18th, 2007 by Brian
This is the fifth in a series of posts analyzing Rosetta Genomics stock.
Most drugs that target proteins work by inhibiting the protein’s function. It’s simply a function of biology; it’s much easier to design a drug that will interfere with a protein’s function than it is to make it overactive. But sometimes (many […]
Filed under: Synta Pharmaceuticals (SNTA) | 1 Comment »